Rxi Pharmaceuticals CEO Buys $3,150 in Stock (RXII)
Rxi Pharmaceuticals (NASDAQ:RXII) CEO Geert Cauwenbergh bought 1,000 shares of the stock in a transaction dated Wednesday, October 9th. The shares were purchased at an average cost of $3.15 per share, for a total transaction of $3,150.00. Following the completion of the transaction, the chief executive officer now directly owns 18,100 shares of the company’s stock, valued at approximately $57,015. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Rxi Pharmaceuticals (NASDAQ:RXII) traded down 12.98% on Wednesday, hitting $2.95. 129,817 shares of the company’s stock traded hands. Rxi Pharmaceuticals has a 1-year low of $1.50 and a 1-year high of $10.74. The stock has a 50-day moving average of $3. and a 200-day moving average of $5.29. The company’s market cap is $34.5 million.
RXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid (NASDAQ:RXII) interference (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.